Printer Friendly

Aastrom Biosciences begins controlled clinical trial for cord blood therapy in leukemia patients.

Aastrom Biosciences, Inc., Ann Arbor, MI, announced it has begun enrolling patients in a controlled clinical trial to evaluate its CB-1 cord blood cell therapy in the treatment of adult leukemia patients. The multi-centered trial is designed to assess the effect that CB-1 cord blood cells can have on enabling successful recovery of normal blood and immune system function following aggressive chemotherapy or radiation therapy.

The company says the trial will evaluate the use of CB-1 cord blood cells to increase the number of cells available for transplant in patients that would not otherwise have enough cells for transplant. The results, if positive, could lead to a new treatment for many leukemia patients who cannot find a suitable bone marrow donor, or for patients that lack a sufficient quantity of cells available, Aastrom says.

Aastrom reports the trial is being conducted under an IDE from FDA and will be conducted at up to 6 sites. The study will enroll adult patients with hemotological malignancies, including those who might otherwise either not be treated, or would receive a sub-standard dose of cord blood stem cells, following myeloablative drug and radiation therapy.

Contact: Todd Simpson - (734) 930-5777
COPYRIGHT 2001 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Aastrom Biosciences begins controlled clinical trial for cord blood therapy in leukemia patients.
Publication:Transplant News
Geographic Code:1USA
Date:Feb 28, 2001
Words:195
Previous Article:Expectation of normal life style unmet for most liver transplant survivors.
Next Article:BioTransplant announces Eligix receives CE Mark from European Community for cell separation product.
Topics:


Related Articles
Aastrom Biosciences receives CE mark for cord blood kit.
Aastrom awarded NIH grant for cord blood transplant program.
Aastrom enters distribution agreements with Gambro and Micromin to distribute AastromReplicell System.
Aastrom Biosciences, Loyola University perform first ever transplants of ex vivo produced stem cells in cancer patients.
Aastrom Biosciences initiates new product program for treatment of bone related diseases.
Aastrom Biosciences begins study of new stem cell transplant procedure in leukemia patients.
Aastrom Biosciences patents cassette approach to growing human cells.
Karmanos Cancer Institute, Aastrom Biosciences create new center for cell therapy.
Aastrom receives patent covering integrated system for producing human cells.
AASTROM BIOSCIENCES REPORTS POSITIVE HUMAN JAW BONE RESULTS.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |